1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Clindamycin Hydrochloride Capsules
Trade Name: Cleocin; Dalacin; SOBELIN; DALACINE ; DALACIN C
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Serious Eye Damage/Eye Irritation: Category 2A
Skin Sensitization: Category 1

EU Classification:

EU Indication of danger: Irritant

EU Risk Phrases:
R36 - Irritating to eyes.
R43 - May cause sensitization by skin contact.

Label Elements

Signal Word: Warning
Hazard Statements:
H319 - Causes serious eye irritation
H317 - May cause an allergic skin reaction
Precautionary Statements:

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P264 - Wash hands thoroughly after handling
P272 - Contaminated work clothing should not be allowed out of the workplace
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing
P337 + P313 - If eye irritation persists: Get medical advice/attention
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental instructions on the administration of antidotes on this label)
P363 - Wash contaminated clothing before reuse

Other Hazards

No data available

Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Talc (non-asbestiform)</td>
<td>14807-96-6</td>
<td>238-877-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Corn Starch</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Clindamycin Hydrochloride</td>
<td>21462-39-5</td>
<td>244-398-6</td>
<td>Xi;R36-43</td>
<td>Acute Tox 5 (H303) Eye Irrit. 2A (H319) Skin Sens.1 (H317)</td>
<td>20-30.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactose</td>
<td>63-42-3</td>
<td>200-559-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.
4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:  Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:  Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:  Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:  Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:  For information on potential signs and symptoms of exposure, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure:  None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:  None

5. FIRE FIGHTING MEASURES

Extinguishing Media:  Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products:  Formation of toxic gases is possible during heating or fire. May include oxides of carbon, nitrogen, sulfur, and chlorine.

Fire / Explosion Hazards:  Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:  Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:  Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.
7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Wash hands and any exposed skin after removal of PPE. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
Refer to available public information for specific member state Occupational Exposure Limits.

Talc (non-asbestiform)
ACGIH Threshold Limit Value (TWA) 2 mg/m³
Australia TWA 2.5 mg/m³
Austria OEL - MAKs 2 mg/m³
Belgium OEL - TWA 2 mg/m³
Bulgaria OEL - TWA 1.0 fiber/cm³
Czech Republic OEL - TWA 2.0 mg/m³
Denmark OEL - TWA 0.3 fiber/cm³
Finland OEL - TWA 0.5 fiber/cm³
Greece OEL - TWA 10 mg/m³
Hungary OEL - TWA 2 mg/m³
Ireland OEL - TWAs 10 mg/m³
Lithuania OEL - TWA 2.0 mg/m³
Netherlands OEL - TWA 0.25 mg/m³
OSHA - Final PELs - Table Z-3 Mineral D: 20 mppcf
Poland OEL - TWA 4.0 mg/m³
Portugal OEL - TWA 1.0 mg/m³
Romania OEL - TWA 2 mg/m³
Slovakia OEL - TWA 2 mg/m³
Slovenia OEL - TWA 10 mg/m³
Spain OEL - TWA 2 mg/m³
Switzerland OEL - TWAs 2 mg/m³
Sweden OEL - TWAs 2 mg/m³

Magnesium stearate
ACGIH Threshold Limit Value (TWA) 10 mg/m³
Lithuania OEL - TWA 5 mg/m³
Sweden OEL - TWAs 5 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Corn Starch

<table>
<thead>
<tr>
<th>ACGIH Threshold Limit Value (TWA)</th>
<th>10 mg/m³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>10.0 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>4.0 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>4 mg/m³</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs:</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>4 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>3 mg/m³</td>
</tr>
</tbody>
</table>

Clindamycin Hydrochloride

| Pfizer OEL TWA-8 Hr:            | 100 µg/m³ |


Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule

Color: Green (75 mg), Light blue / green (150 mg), light blue (300 mg)

Odor: No data available.

Molecular Formula: Mixture

Odor Threshold: No data available.

Molecular Weight: Mixture

Solvent Solubility: No data available

Water Solubility: No data available

pH: No data available.

Melting/Freezing Point (°C): No data available

Boiling Point (°C): No data available.

Partition Coefficient: (Method, pH, Endpoint, Value) Clindamycin Hydrochloride

Lactose

No data available

PZ00138
9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decomposition Temperature (°C)</td>
<td>No data available</td>
</tr>
<tr>
<td>Evaporation Rate (Gram/s)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Pressure (kPa)</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor Density (g/ml)</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative Density</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td>No data available</td>
</tr>
</tbody>
</table>

**Flammability:**
- Autoignition Temperature (Solid) (°C): No data available
- Flammability (Solids): No data available
- Flash Point (Liquid) (°C): No data available
- Upper Explosive Limits (Liquid) (% by Vol.): No data available
- Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>No data available</td>
</tr>
<tr>
<td>Chemical Stability</td>
<td>Stable under normal conditions of use.</td>
</tr>
<tr>
<td>Possibility of Hazardous Reactions</td>
<td>No data available</td>
</tr>
<tr>
<td>Oxidizing Properties</td>
<td>No data available</td>
</tr>
<tr>
<td>Conditions to Avoid</td>
<td>Fine particles (such as dust and mists) may fuel fires/explosions.</td>
</tr>
<tr>
<td>Incompatible Materials</td>
<td>As a precautionary measure, keep away from strong oxidizers</td>
</tr>
<tr>
<td>Hazardous Decomposition Products</td>
<td>No data available</td>
</tr>
</tbody>
</table>

11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:**
The information included in this section describes the potential hazards of the individual ingredients.

**Known Clinical Effects:**
Adverse effects associated with therapeutic use include gastrointestinal disturbances such as nausea, dyspepsia, and vomiting and gastrointestinal irritation. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions.

**Acute Toxicity: (Species, Route, End Point, Dose)**

<table>
<thead>
<tr>
<th>Material</th>
<th>Species</th>
<th>Route</th>
<th>End Point</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn Starch</td>
<td>Rat</td>
<td>Oral</td>
<td>LD 50</td>
<td>2618 mg/kg</td>
</tr>
<tr>
<td>Clindamycin Hydrochloride Capsules</td>
<td>Rat</td>
<td>Sub-tenon injection (eye)</td>
<td>LD 50</td>
<td>279 mg/kg</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Mouse</td>
<td>Oral</td>
<td>LD 50</td>
<td>891 mg/kg</td>
</tr>
<tr>
<td>Talc (non-asbestiform)</td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>LD 50</td>
<td>1479 mg/kg</td>
</tr>
<tr>
<td>Talc (non-asbestiform)</td>
<td>Mouse</td>
<td>Intravenous</td>
<td>LD 50</td>
<td>143 mg/kg</td>
</tr>
</tbody>
</table>

PZ00138
11. TOXICOLOGICAL INFORMATION

Talc (non-asbestiform)
Rat Oral LD50 > 1600 mg/kg

Magnesium stearate
Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Clindamycin Hydrochloride
Eye Irritation Rat No effect
Eye Irritation Rabbit Moderate
Skin Irritation Rat No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Clindamycin Hydrochloride
6 Month(s) Rat Oral 600 mg/kg/day NOAEL No effects at maximum dose
6 Month(s) Dog Oral 600 mg/kg/day LOAEL Gastrointestinal system
1 Year(s) Rat Oral 300 mg/kg/day NOAEL No effects at maximum dose
1 Month(s) Dog Oral 300 mg/kg/day NOAEL No effects at maximum dose

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Clindamycin Hydrochloride
Reproductive & Fertility Rat Oral 300 mg/kg/day NOAEL Fertility
Embryo / Fetal Development Mouse Oral 600 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rat Oral 600 mg/kg/day NOAEL Not Teratogenic
Embryo / Fetal Development Rat Subcutaneous 250 mg/kg/day NOAEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Clindamycin Hydrochloride
Bacterial Mutagenicity (Ames) Salmonella Negative
In Vitro Micronucleus Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Talc (non-asbestiform)
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity: No data available
Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, and Subdivision B.

Lactose

CERCLA/SARA 313 Emission reporting Not Listed
California Proposition 65 Not Listed
Inventory - United States TSCA - Sect. 8(b) Present
Australia (AICS): Present
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List 200-559-2
15. REGULATORY INFORMATION

Talc (non-asbestiform)
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 238-877-9

Magnesium stearate
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

Corn Starch
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register:
- EU EINECS/ELINCS List: 232-679-6

Clindamycin Hydrochloride
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: 244-398-6

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

- Acute toxicity, oral-Cat.5; H303 - May be harmful if swallowed
- Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
- Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

R36 - Irritating to eyes.
R43 - May cause sensitization by skin contact.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information.

Revision date: 04-Nov-2014
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.
End of Safety Data Sheet